We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

WERFEN

Werfen provides diagnostic instruments for critical care and hemostasis to meet the testing needs of medical professi... read more Featured Products: More products

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Clinical Utility of Anti-Platelet Factor 4 ELISA Test Characterized

By LabMedica International staff writers
Posted on 29 Nov 2015
Print article
LIFECODES PF4 Enhanced and PF4 IgG anti-platelet factor 4 enzyme-linked immunosorbent assay
LIFECODES PF4 Enhanced and PF4 IgG anti-platelet factor 4 enzyme-linked immunosorbent assay (Photo courtesy of Werfen)
Diagnosing heparin-induced thrombocytopenia, a potentially catastrophic immune-mediated disorder, continues to pose significant challenges for clinicians, as both clinical and laboratory tools lack specificity.

There is mounting evidence supporting a positive correlation between definitive heparin-induced thrombocytopenia and optical density (OD) positivity from the widely available anti-platelet factor 4 enzyme-linked immunosorbent assays (PF4 ELISAs); however, the clinical features distinguishing these patients remain poorly understood.

Scientists at the NYU Langone Medical Center (New York, NY, USA) conducted a case-controlled, retrospective chart review of patients from two large, urban academic institutions who underwent a PF4 ELISA at a central laboratory between July 1, 2009, and July 1, 2014. PF4 ELISA assay is a polyimmunoglobulin assay (anti-immunoglobulin G (IgG)/IgAIg/M) utilizing 60 units of heparin in the positive control. Internal positive and negative control values were recorded for each patient’s PF4 ELISA.

The PF4 ELISA testing was performed using the LIFECODES PF4 Enhanced assay kit (Immucor GTI Diagnostics, Inc., Waukesha, WI, USA). In total, 184 negative patients (OD less than 0.7), and 121 positive patients (OD greater than 0.7), including 74 low-positive patients (0.7, OD less than 1.4) and 47 high-positive patients (OD greater than 1.4) were identified. Several clinical variables were significantly different in the negative group compared with the positive group, including hospital day, previous admission within the past three months, and the presence of a new thrombus. However, many of these variables were not different between the negative and low-positive group, and were only distinct between the negative and high-positive group. When the low-positive and high-positive groups were compared, only the 4T score was significantly different.

The authors concluded that patients with high-positive ODs represent a distinct clinical group when compared with low-positive ODs. However, no single characteristic analyzed was able to distinguish those with a low-positive PF4 ELISA OD and those with a high-positive PF4 ELISA OD. Our findings reinforce the clinical utility of the 4T score, which was the only clinical variable that significantly distinguished low-positive and high-positive groups. The study was published on November 19, 2015, in the Journal of Blood Medicine.

Related Links:

NYU Langone Medical Center 
Immucor GTI Diagnostics, Inc. 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.